A5101746379- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Acute Lymphoblastic Leukemia research
- Medicinal Plants and Bioactive Compounds
- Diagnosis and treatment of tuberculosis
- Lung Cancer Treatments and Mutations
- Liver Diseases and Immunity
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Systems, Economic Evaluations, Quality of Life
- Medicinal Plant Research
- Systemic Lupus Erythematosus Research
- Phytochemicals and Antioxidant Activities
University of Chicago
2020-2022
Medications are major cost drivers in the treatment of patients with inflammatory bowel disease. Recent analyses suggest that there is no added efficacy continuing nor harm stopping 5-aminosalicylate (ASA) therapy disease escalated to biological therapies or tofacitinib. We assessed cost-effectiveness discontinuing 5-ASA ulcerative colitis on tofacitinib, compared therapy.We performed a analysis biologic and tofacitinib same without 5-ASA. Our primary outcome was determine whether...
Interruptions in infliximab therapy are associated with the development of antibodies to (ATI), infusion reactions (IRs), and loss response. Despite these challenges, recent observational studies suggest that reinitiating after a drug holiday can be safe effective. We assessed utility our protocol for restarting using early serum ATI measurements.A retrospective cohort study patients restarted on at least 6-month holiday. The was divided into 2 groups: "therapeutic monitoring (TDM) group,"...